(Q37378350)

English

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

scientific article published on September 2009

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

20 August 2017

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus (English)

1 reference

Europe PubMed Central

20 August 2017

0 references

0 references

systemic lupus erythematosus

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

Michelle A. Petri

7

object named as

Michelle A Petri

1 reference

Europe PubMed Central

20 August 2017

6

object named as

Joan T Merrill

1 reference

Europe PubMed Central

20 August 2017

Ellen M Ginzler

8

object named as

Ellen M Ginzler

1 reference

Europe PubMed Central

20 August 2017

author name string

Daniel J Wallace

1

1 reference

Europe PubMed Central

20 August 2017

William Stohl

2

1 reference

Europe PubMed Central

20 August 2017

Richard A Furie

3

1 reference

Europe PubMed Central

20 August 2017

Jeffrey R Lisse

4

1 reference

Europe PubMed Central

20 August 2017

James D McKay

5

1 reference

Europe PubMed Central

20 August 2017

W Winn Chatham

9

1 reference

Europe PubMed Central

20 August 2017

W Joseph McCune

10

1 reference

Europe PubMed Central

20 August 2017

Vivian Fernandez

11

1 reference

Europe PubMed Central

20 August 2017

Marc R Chevrier

12

1 reference

Europe PubMed Central

20 August 2017

Z John Zhong

13

1 reference

Europe PubMed Central

20 August 2017

William W Freimuth

14

1 reference

Europe PubMed Central

20 August 2017

publication date

1 September 2009

1 reference

Europe PubMed Central

20 August 2017

Arthritis & Rheumatology

1 reference

Europe PubMed Central

20 August 2017

61

1 reference

Europe PubMed Central

20 August 2017

9

1 reference

Europe PubMed Central

20 August 2017

1168-1178

1 reference

Europe PubMed Central

20 August 2017

Novel evidence-based systemic lupus erythematosus responder index

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BLyS inhibition eliminates primary B cells but leaves natural and acquired humoral immunity intact

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Biologic activity and safety of belimumab, a neutralizing anti-B-lymphocyte stimulator (BLyS) monoclonal antibody: a phase I trial in patients with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Association of plasma B lymphocyte stimulator levels and disease activity in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

APRIL is critical for plasmablast survival in the bone marrow and poorly expressed by early-life bone marrow stromal cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Paucity of clinical disease despite serological autoimmunity and kidney pathology in lupus-prone New Zealand mixed 2328 mice deficient in BAFF

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

B lymphocyte stimulator (BLyS) isoforms in systemic lupus erythematosus: disease activity correlates better with blood leukocyte BLyS mRNA levels than with plasma BLyS protein levels

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Challenges in bringing the bench to bedside in drug development for SLE.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BCMA is essential for the survival of long-lived bone marrow plasma cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Generation and characterization of LymphoStat‐B, a human monoclonal antibody that antagonizes the bioactivities of B lymphocyte stimulator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BAFF selectively enhances the survival of plasmablasts generated from human memory B cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BAFF/BLyS receptor 3 binds the B cell survival factor BAFF ligand through a discrete surface loop and promotes processing of NF-kappaB2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Association of BAFF/BLyS overexpression and altered B cell differentiation with Sjögren's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Identification of a novel receptor for B lymphocyte stimulator that is mutated in a mouse strain with severe B cell deficiency

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Elevated serum B lymphocyte stimulator levels in patients with systemic immune-based rheumatic diseases.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Cutting edge: a role for B lymphocyte stimulator in systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Attenuation of apoptosis underlies B lymphocyte stimulator enhancement of humoral immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

TACI is a TRAF-interacting receptor for TALL-1, a tumor necrosis factor family member involved in B cell regulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

TACI and BCMA are receptors for a TNF homologue implicated in B-cell autoimmune disease

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Severe B cell hyperplasia and autoimmune disease in TALL-1 transgenic mice

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Mice transgenic for BAFF develop lymphocytic disorders along with autoimmune manifestations

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

6 September 2017

BAFF supports human B cell differentiation in the lymphoid follicles through distinct receptors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

14 September 2017

From BILAG to BLIPS--disease activity assessment in lupus past, present and future

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

28 September 2017

The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

26 June 2018

BAFF enhances chemotaxis of primary human B cells: a particular synergy between BAFF and CXCL13 on memory B cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

Combined oral contraceptives in women with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

A trial of contraceptive methods in women with systemic lupus erythematosus

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

The effect of combined estrogen and progesterone hormone replacement therapy on disease activity in systemic lupus erythematosus: a randomized trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

Correlation between circulating CD27high plasma cells and disease activity in patients with systemic lupus erythematosus.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren's syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

Overview of the SF-36 Health Survey and the International Quality of Life Assessment (IQOLA) Project.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2758229

2 September 2018

Classification and definition of major flares in SLE clinical trials

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improvement in health-related quality of life in patients with SLE following sustained reductions in anti-dsDNA antibodies

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Chronic administration of belimumab, a BLyS antagonist, decreases tissue and peripheral blood B-lymphocyte populations in cynomolgus monkeys: pharmacokinetic, pharmacodynamic, and toxicologic effects

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

B cell depletion therapy in systemic lupus erythematosus: effect on autoantibody and antimicrobial antibody profiles

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Definition and treatment of lupus flares measured by the BILAG index

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

TACI-Ig neutralizes molecules critical for B cell development and autoimmune disease. impaired B cell maturation in mice lacking BLyS

1 reference

https://pubmed.ncbi.nlm.nih.gov/19714604

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1002/ART.24699

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

1 reference

Europe PubMed Central

20 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q37378350&oldid=2094929334"